09:39 AM EDT, 03/28/2025 (MT Newswires) -- Aptose Biosciences ( APTO ) on Friday said its 2024 net loss halved due to lower expenses.

Net loss for the year ended Dec. 31 fell to $25.4 million, compared with a loss of $51.2 million for the previous year.

Research and development expenses decreased to $15.1 million from $36.8 million.

The company reported total cash of $6.7 million at the end of 2024, which it said is sufficient to fund operations including research and development until April.

Price: 4.80, Change: -0.63, Percent Change: -11.60